136 related articles for article (PubMed ID: 17565005)
1. The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Lam W; Leung CH; Bussom S; Cheng YC
Mol Pharmacol; 2007 Sep; 72(3):536-44. PubMed ID: 17565005
[TBL] [Abstract][Full Text] [Related]
2. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
3. Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine).
Lam W; Park SY; Leung CH; Cheng YC
Mol Pharmacol; 2006 May; 69(5):1607-14. PubMed ID: 16481390
[TBL] [Abstract][Full Text] [Related]
4. A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.
Chou KM; Kukhanova M; Cheng YC
J Biol Chem; 2000 Oct; 275(40):31009-15. PubMed ID: 10906132
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.
Kim TE; Park SY; Hsu CH; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Aug; 66(2):285-92. PubMed ID: 15266019
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
7. UMP/CMPK is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human RKO cells.
Hu R; Lam W; Hsu CH; Cheng YC
PLoS One; 2011 May; 6(5):e19490. PubMed ID: 21559290
[TBL] [Abstract][Full Text] [Related]
8. Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
Bierau J; van Gennip AH; Leen R; Meinsma R; Caron HN; van Kuilenburg AB
Cancer Chemother Pharmacol; 2006 Jan; 57(1):105-13. PubMed ID: 16133534
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
10. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells.
Grove KL; Cheng YC
Cancer Res; 1996 Sep; 56(18):4187-91. PubMed ID: 8797590
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.
Grove KL; Guo X; Liu SH; Gao Z; Chu CK; Cheng YC
Cancer Res; 1995 Jul; 55(14):3008-11. PubMed ID: 7606719
[TBL] [Abstract][Full Text] [Related]
12. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Beauséjour CM; Gagnon J; Primeau M; Momparler RL
Biochem Biophys Res Commun; 2002 May; 293(5):1478-84. PubMed ID: 12054682
[TBL] [Abstract][Full Text] [Related]
14. Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
van Bree C; Rodermond H; Leen R; Medema J; van Kuilenburg A
Br J Cancer; 2008 Apr; 98(7):1226-33. PubMed ID: 18349845
[TBL] [Abstract][Full Text] [Related]
15. Beta-L-1,3-dioxolane-cytidine: a novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro.
Schwartz PM; Haggerty JG; Cheng YC
Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):207-13. PubMed ID: 9885404
[TBL] [Abstract][Full Text] [Related]
16. Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides.
Lau JP; Weatherdon KL; Skalski V; Hedley DW
Br J Cancer; 2004 Sep; 91(6):1166-73. PubMed ID: 15316562
[TBL] [Abstract][Full Text] [Related]
17. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Gandhi V; Mineishi S; Huang P; Yang Y; Chubb S; Chapman AJ; Nowak BJ; Hertel LW; Plunkett W
Semin Oncol; 1995 Aug; 22(4 Suppl 11):61-7. PubMed ID: 7481847
[TBL] [Abstract][Full Text] [Related]
18. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
19. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Veltkamp SA; Pluim D; van Eijndhoven MA; Bolijn MJ; Ong FH; Govindarajan R; Unadkat JD; Beijnen JH; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2415-25. PubMed ID: 18723487
[TBL] [Abstract][Full Text] [Related]
20. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Weitman S; Marty J; Jolivet J; Locas C; Von Hoff DD
Clin Cancer Res; 2000 Apr; 6(4):1574-8. PubMed ID: 10778991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
